

21st June 2024

BSE LIMITED Phiroze Jeejeebhoy Towers Dalal Street, Mumbai – 400001 Scrip Code: BSE – AJANTPHARM 532331	National Stock Exchange of India, Exchange Plaza, 5 th Floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051 Scrip Code: NSE AJANTPHARM EQ
--	--

Sub.: Disclosure under regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 as amended (“SEBI SAST Regulations”)

With reference to the captioned subject, we are in receipt of intimation from Mr. Yogesh M Agrawal, trustee Yogesh Agrawal Trust, Promoter, on behalf of all Promoters and Promoter group of Ajanta Pharma Limited (“the Company”) pursuant to Regulation 29(2) of the SEBI SAST Regulations, with respect to reduction in shares and voting rights in the Company pursuant to shares tendered in the Buy-back offer and resultant extinguishment of equity shares.

In this regard, we are submitting herewith disclosure received from Promoters pursuant to Regulation 29(2) of the SEBI SAST Regulations.

Kindly take the same on record.
Thanking you,

Yours faithfully,
For Ajanta Pharma Limited.

Gaurang Shah
Sr. VP – Legal & Company Secretary

June 21, 2024

To,
BSE Limited
PJ Towers, Dalal Street,
Mumbai 400 001,
Maharashtra, India
Scrip Code: 532331
Scrip ID: AJANTPHARM

To
National Stock Exchange of India Limited
C-1 Block G,
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051,
Maharashtra, India
Symbol: AJANTPHARM

SUB: Disclosure under Regulation 29(2) of the SEBI (Substantial Acquisition and Takeover) Regulations 2011.

Dear Sir / Madam,

Please find enclosed herewith the disclosure under Regulations 29(1) and 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 for transaction in the equity shares of Ajanta Pharma Limited.

Kindly take the same on your records.

Thanking You.

Yours faithfully,

YOGESH
MANNALAL
AGRAWAL
Digitally signed by
YOGESH MANNALAL
AGRAWAL
Date: 2024.06.21
15:20:55 +05'30'

Yogesh M Agrawal
(For and on behalf of Promoters and
Promoter Group of Ajanta Pharma Limited)

Date: June 21, 2024

Place: Mumbai

Encl: As above.

**Disclosure under Regulation 29(2) of
SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011**

Name of the Target Company (TC)	Ajanta Pharma Limited		
Name(s) of the acquirer/ seller and Persons Acting in Concert (PAC) with the acquirer	1. Yogesh M Agrawal, trustee Yogesh Agrawal Trust 2. Rajesh M Agrawal, trustee Rajesh Agrawal Trust 3. Ravi P Agrawal, trustee Ravi Agrawal Trust 4. Aayush M. Agrawal, trustee Aayush Agrawal Trust 5. Ganga Exports being represented by Yogesh Agrawal, Rajesh Agrawal & Ravi Agrawal 6. Ravi P Agrawal 7. Aayush M Agrawal 8. Gabs Investments Private Limited 9. Mannalal B Agrawal		
Whether the acquirer/ seller belongs to Promoter / Promoter Group	Yes		
Name(s) of the Stock Exchange(s) where the shares of the TC are Listed	BSE Limited (BSE) National Stock Exchange of India Limited (NSE)		
Details of the acquisition / disposal are as follows:	Number	% w.r.t. total share/voting capital wherever applicable(*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the acquisition under consideration, holding of:			
a) Shares carrying voting rights (As per Annexure-A)	8,33,73,054	66.21%	66.21%
b) Shares in the nature of encumbrance (pledge/ lien/ non disposal undertaking/ others)	91,22,644 [#]	7.30% [#]	7.30% [#]
c) Voting rights (VR) otherwise than by shares	Nil	Nil	Nil
d) Warrants/ convertible securities/ any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	Nil	Nil	Nil
e) Total (a+b+c+d) # From and out of the shares mentioned in (a) above	8,33,73,054	66.21%	66.21%
Details of acquisition/ disposal			
a) Shares carrying voting rights acquired/ disposed	6,09,277	0.49% ^{\$}	0.49% ^{\$}
b) VRs acquired/ disposed otherwise than by shares	Nil	Nil	Nil
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC acquired	Nil	Nil	Nil
d) Shares encumbered / invoked / released by the acquirer	Nil	Nil	Nil
e) Total (a+b+c+d)	6,09,277	0.49%^{\$}	0.49%^{\$}

After the acquisition/ sale, holding of acquirer along with PACs of:			
a) Shares carrying voting rights (As per Annexure-A)	8,27,63,777	66.27%	66.27%
b) Shares encumbered with the acquirer	91,22,644 [#]	7.30% [#]	7.30% [#]
c) VRs otherwise than by shares	Nil	Nil	Nil
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC after acquisition	Nil	Nil	Nil
e) Total (a+b+c+d)	8,27,63,777	66.27%	66.27%
#From and out of the shares mentioned in (a) above			
Mode of acquisition/ sale (e.g. open market / off-market / public issue / rights issue / preferential allotment / inter-se transfer etc).	Buyback of Shares through Tender Offer. The promoters had participated in buyback and have tendered their shares. Pre and post buyback Promoter shareholding is enclosed below in Annexure A		
Date of acquisition of / sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable	Wednesday, June 19, 2024		
Equity share capital / total voting capital of the TC before the said acquisition/ sale Buyback	₹ 25,18,33,310/- consisting of 12,59,16,655 Equity Shares having a face value of ₹ 10/-		
Equity share capital/ total voting capital of the TC after the said acquisition/ sale Buyback	₹ 24,97,75,548/- consisting of 12,48,87,774 Equity Shares having a face value of ₹ 2/-		
Total diluted share/voting capital of the TC after the said acquisition/ sale Buyback	₹ 24,97,75,548/- consisting of 12,48,87,774 Equity Shares having a face value of ₹ 2/-		

(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Reg. 31 of the Listing Regulations.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(§) Percentage has been calculated on post buyback number of shares.

Thanking You.

Yours faithfully,

YOGESH Digitally signed by
MANNALAL YOGESH MANNALAL
AGRAWAL AGRAWAL
Date: 2024.06.21
15:21:29 +05'30'

Yogesh M Agrawal
(For and on behalf of Promoters and
Promoter Group of Ajanta Pharma Limited)

Place: Mumbai

Date: June 21, 2024

Encl: Annexure – A

Annexure – A

Shareholder	Before the proposed transaction			Details of the Transaction			After the proposed transaction		
	No. of Shares/ Voting Rights	% w.r.t total share capital of TC	% w.r.t total share capital of TC (diluted basis)	No. of Shares/ Voting Rights Disposed	% w.r.t total share capital of TC	% w.r.t total share capital of TC (diluted basis)	No. of Shares/ Voting Rights	% w.r.t total share capital of TC	% w.r.t total share capital of TC (diluted basis)
Promoters & Promoters Group									
Yogesh M Agrawal, trustee, Yogesh Agrawal Trust	1,82,33,038	14.48	14.48	1,54,891	0.12	0.12	1,80,78,147	14.48	14.48
Rajesh M Agrawal, trustee, Rajesh Agrawal Trust	1,82,33,039	14.48	14.48	1,54,891	0.12	0.12	1,80,78,148	14.48	14.48
Ravi P Agrawal, trustee, Ravi Agrawal Trust	1,63,86,623	13.01	13.01	1,43,719	0.12	0.12	1,62,42,904	13.01	13.01
Ravi P Agrawal	2,85,000	0.23	0.23	-	0.00	0.00	2,85,000	0.23	0.23
Aayush M Agrawal, trustee, Aayush Agrawal Trust	1,42,37,664	11.31	11.31	1,24,740	0.10	0.10	1,41,12,924	11.30	11.30
Aayush M Agrawal	30,000	0.02	0.02	-	-	-	30,000	0.02	0.02
Ganga Exports being represented by Yogesh Agrawal, Rajesh Agrawal & Ravi Agrawal	33,79,297	2.68	2.68	31,036	0.02	0.02	33,48,261	2.68	2.68
Gabs Investments Private Limited	1,25,88,393	10.00	10.00	-	-	-	1,25,88,393	10.08	10.08
Mannalal B Agrawal	0	0.00	0.00	-	-	-	0	0.00	0.00
Total Promoter & Promoter Group	8,33,73,054	66.21	66.21	6,09,277	0.49	0.49	8,27,63,777	66.27	66.27

Note: The aforesaid acquisitions of voting rights in the shares are pursuant to tendering of Shares in Buyback.

Yours faithfully,

YOGESH
MANNALAL
AGRAWAL

Digitally signed by
YOGESH MANNALAL
AGRAWAL
Date: 2024.06.21
15:21:48 +05'30'

Yogesh M Agrawal
(For and on behalf of Promoters and Promoter Group of Ajanta Pharma Limited)

Place: Mumbai

Date: June 21, 2024